Bioconjugation in pharmaceutical chemistry

Farmaco

Volumn 54, Issue 8, 1999, Pages 497-516

  Veronese, F M ^a   Morpurgo, M ^a  

^a UNIVERSITY OF PADOVA   (Italy)

Author keywords

Bioconjugation; Drugs; Pharmaceutical chemistry

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; ASPARAGINASE; DEXTRAN; DRUG CARRIER; INTERLEUKIN 2; INTERLEUKIN 6; MACROGOL; PEPTIDE; POLYMER; STYRENE MALEIC ANHYDRIDE COPOLYMER; ZINOSTATIN;

BIOAVAILABILITY; DRUG CONJUGATION; DRUG DELIVERY SYSTEM; DRUG PENETRATION; DRUG STABILITY; DRUG TARGETING; ENDOCYTOSIS; IMMUNOGENICITY; MOLECULAR WEIGHT; REVIEW;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; HUMANS; PHARMACEUTICAL PREPARATIONS; POLYMERS;

EID: 0032870935     PISSN: 0014827X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-827X(99)00066-X     Document Type: Review

References (149)

1. Ringsdorf H. Structure and properties of pharmacologically active polymers. J. Polym. Sci., Polym. Symp. 51:1975;135-153.
2. Monfardini C., Veronese F.M. Stabilization of substances in circulation. Bioconjug. Chem. 9:1998;418-450.
3. Nucci M.L., Shorr R., Abuchoski A. The therapeutic value of poly(ethylene glycol)-modified proteins. Adv. Drug Deliv. Rev. 6:1991;133-151.
4. Delgado C., Francis G.E., Derek F. The uses and properties of PEG-linked proteins. Crit. Rev. Ther. Drug Carr. Syst. 9:1992;249-304.
5. Katre N.V. The conjugation of proteins with poly(ethylene glycol) and other polymers. Altering properties of proteins to enhance their therapeutic potential. Adv. Drug Deliv. Rev. 10:1993;91-114.
6. Zalipsky S. Chemistry of poly(ethylene glycol) conjugates with biologically active molecules. Adv. Drug Deliv. Rev. 16:1995;157-182.
7. Duncan R. Drug-polymer conjugates: potential for improved chemotherapy. Anti-Cancer Drugs. 3:1992;175-210.
8. Maeda H. SMANCS and polymer conjugated macromolecular drugs: advantages in cancer chemotherapy. Adv. Drug Deliv. Rev. 6:1991;181-202.
9. Putnam D., Kopecek J. Polymer conjugates with anticancer activity. Adv. Polym. Sci. 122:1995;55-123.
10. Sehon A.H. Suppression of antibody responses by conjugates of antigens and monomethoxypoly(ethylene glycol). Adv. Drug Deliv. Rev. 6:1991;203-217.
11. Dreborg S., Akerblom E.B. Immunotherapy with monomethoxypoly(ethylene glycol) modified allergens. Crit. Rev. Ther. Drug Carr. Syst. 6:1990;315-365.
12. Russell-Jones G.J. The potential use of receptor-mediated endocytosis for oral drug delivery. Adv. Drug Deliv. Rev. 20:1996;83-97.
13. Okamoto C.T. Endocytosis and transcytosis. Adv. Drug Deliv. Rev. 29:1998;215-228.
14. Takakura Y., Mahoto R.I., Hashida M. Extravasation of macromolecules. Adv. Drug Deliv. Rev. 34:1998;93-108.
15. Wawrzynczak E.J., Thorpe P.E. Effect of chemical linkage upon the stability and cytotoxic activity of A chain immunotoxins. Frankel A.E. Immunotoxins. 1988;239-251 Kluwer, Boston.
16. Wawrzynczak E.J. Rational design of immunotoxins: current progress and future prospects. Anti-Cancer Drug Des. 7:1992;427-441.
17. Vitetta E.S., Thorpe P.E., Uhr J.W. Immunotoxins: magic bullets or misguided missiles? Immunol. Today. 14:1993;252-259.
18. P. Erhlich, A general review of the recent work in immunity, in: Collected Papers of Paul Erhlich, vol. 2, Immunology and Cancer Research, Pergamon, London, 1956, pp. 442-447.
19. Duncan R., Kopeckova-Rejmanova P., Strohlam J., Hume I.C., Lloyd J.B., Koyecek J. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 2. Evaluation of daunomicin conjugates in vivo against L 1210 leukaemia. Br. J. Cancer. 57:1988;147-156.
20. Duncan R., Seymour L.W., O'Hare K.B., Flanagan P.A., Wedge S., Ulbrich K., Strohalm J., Subr V., Spreafico F., Grandi M., Ripamonti M., Farao M., Suarato A. Preclinical evaluation of polymer-bound doxorubicin. J. Controlled Release. 18:1992;123-132.
21. Duncan R., Hume I.C., Kopeckova P., Ulbrich K., Strohalm J., Kopecek J. Anticancer agents coupled to N-(2-hydroxypropyl)methacrylamide copolymers. 3. Evaluation of adriamycin conjugates against mouse leukemia L1210 in vivo. J. Controlled Release. 10:1989;51-63.
22. O'Hare K., Duncan R., Strohlam J., Ulbrich K., Kopeckova P. Polymeric drug carriers containing doxorubicin and melanocyte-stimulating hormone: in vitro and in vivo evaluation against murine melanoma. J. Drug Target. 1:1993;217-229.
23. Seymour L.W., Flanagan P.A., Al-Shamkhani A., Subr V., Ulbrich K., Cassidy J., Duncan R. Synthetic polymers conjugated to monoclonal antibodies: vehicles for tumor-targeted drug delivery. Sel. Cancer Ther. 7:1991;59-73.
24. Duncan R., Seymour L.W., Scarlett L., Llyod J.B., Rejmanova P., Kopecek J. N-(2-Hydroxypropyl)methacrylamide copolymers with pendant galactosamine residues. Fate after intravenous administration in rats. Biochim. Biophys. Acta. 880:1986;62-71.
25. Seymour L.W., Ulbrich K., Strahalm J., Kopecek J., Duncan R. Pharmacokinetics of polymer-bound adriamycin. Biochem. Pharmacol. 39:1990;1125-1131.
26. Rizzo V., Pinciroli V. La caratterizzazione analitica di coniugati polimero-farmaco. Chim. Ind. 80:1998;901-905.
27. Configliacchi E., Razzano G., Rizzo V., Vigevani A. HPLC methods for the determination of bound and free doxorubicin, and of bound and free galactosamine, in methacrylamide polymer-drug conjugates. J. Pharm. Biomed. Anal. 15:1996;123-129.
28. Duncan R., Hume I.C., Yardley H.J., Flanagan P.A., Ulbrich K., Subr V., Strohalm J. Macromolecular prodrugs for use in targeted cancer chemotherapy: melphalan covalently coupled to N-(2-hydroxypropyl)methacrylamide copolymers. J. Controlled Release. 16:1991;121-136.
29. Ulbrich K., Zacharieva E., Kopecek J., Hume I.C., Duncan R. Polymer bound derivatives of sarcolysin and their antitumor activity against mouse and human leukaemia in vitro. Makromol. Chem. 188:1987;2497-2509.
30. Ohya Y., Kuroda H., Hirai K., Ouchi T. Synthesis and cytotoxic activity of conjugates of monomethoxy poly(ethylene glycol) end capped with doxorubicin via ester, amide, or Schiff base bond. J. Bioact. Comp. Polym. 10:1995;51-66.
31. Kwon G., Suwa S., Yokoyama M., Okano T., Sakurai Y., Kataoka K. Enhanced tumor accumulation and prolonged circulation times of micelle-forming poly(ethylene oxide-aspartate) block copolymers-adryamycin conjugates. J. Controlled Release. 29:1994;17-23.
32. Caliceti P., Monfardini C., Sartore L., Schiavon O., Baccichetti F., Carlassare F., Veronese F.M. Preparation and properties of monomethoxypoly(ethylene glycol) doxorubicin conjugates linked by an amino acid or peptide as spacer. Farmaco. 48:1993;919-932.
33. Greenwald R.B., Pendri A., Conover C., Gilbert C., Yang R., Xia J. Drug delivery system: camptothecin 20-0-poly(ethylene glycol) ester transport forms. J. Med. Chem. 39:1996;1938-1940.
34. Nathan A., Zalipsky S., Kohn J. Strategies for covalent attachment of doxorubicin to poly(PEG-Lys), a new water soluble poly(ether urethane). J. Bioact. Comp. Pol. 9:1994;239-251.
35. Nichifor M., Coessen V., Schacht E.M. Macromolecular prodrugs of 5-fluoruracil. 1. Synthesis and hydrolytic stability. J. Bioac. Comp. Polym. 10:1995;199-222.
36. Coessen V., Schacht E.H., Domurado D. Synthesis and in vitro stability of macromolecular prodrugs of norfloxacin. J. Controlled Release. 47:1997;283-291.
37. Greenwald R.B., Gilbert C.W., Pendri A.D., Conover C., Xia J., Martinez A. Drug delivery systems: water soluble taxol 2′-poly(ethylene glycol) ester prodrugs - design and in vivo effectiveness. J. Med. Chem. 39:1996;424-431.
38. Bentley M.D., Chung B.Y., Ellis W., Mc Greevy F. Polymer Prepr. 38:1997;584-585.
39. Merigan T.C., Regelson W. Interferon induction in man by a synthetic polyanion of defined composition. New Engl. J. Med. 277:1967;1283-1287.
40. Hirano T., Ohashi S., Morimoto K., Tsuda T., Kobayashi Y., Tsuksgoshi S. Synthesis of antitumor-active conjugates of adriamicin or daunomycin with the copolymer of divinyl ether and maleic anhydride. Makromol. Chem. 187:1986;2815-2824.
41. Hirano T., Ringsdorf H., Zaharko D. Antitumor activity of monomeric and polymeric cyclophosphamide derivative compound with in vitro hydrolysis. Cancer Res. 40:1980;2263-2267.
42. Zunino F., Pratesi G., Pezzoni G. Increased therapeutic efficacy and reduced toxicity of doxorubicin linked to pyran copolymer via the side-chain of the drug. Cancer Treat. Rep. 71:1987;367-373.
43. Bogliolo G., Muzzulini C., Lerza R., Pannacciulli I. Activity of doxorubicin linked to poly-L-aspartic acid on normal murine hematopoietic progenitor cells. Cancer Treat. Rep. 70:1986;1275-1281.
44. G. Decher, M. Emmelius, H. Ringsdorf, Synthesis and antitumor activity of daunorubicin-containing polymers, in: 26th Microsymposium on Polymers in Medicine and Biology, Prague, Czechoslovakia, 1984, pp. 40-41.
45. Hrdina R., Bogusova T.A., Kunova A., Kvetina J. Changes in the toxicity and therapeutic efficacy of daunorubicin linked with a biodegradable carrier. Neoplasma. 38:1991;265-273.
46. Trouet A., Masquelier M., Baurain R., Campeneere D.D. A covalent linkage between daunorubicin and proteins that is stable in serum and reversible by lysosomal hydrolases, as required for a lysosomotropic drug-carrier conjugate: in vitro and in vivo studies. Proc. Natl. Acad. Sci. USA. 79:1982;626-629.
47. K. Fujii, T. Imai, M. Otagiri, Control of pharmacokinetics and nefrotoxicity of cis-DDP by alginate, 23rd Proc. Int. Symp. Controlled Release Bioact. Mater., 1996, pp. 5018-5019.
48. Ouchi T., Fujiino A., Tanaka K., Banba T. Synthesis and antitumor activity of conjugates of poly(α-malic acid) and fluorouracils bound via esters, amide and carbamoyl bonds. J. Controlled Release. 12:1990;143-153.
49. G. Horpel W. Klesse, H. Ringsdorf, Micelle forming co- and block-polymers for sustained drug release, IUPAC Proc. Int. Symp. Macromol., Amherst, MA, 1982, p. 346.
50. Giammona G., Carlisi B., Pitarresi G., Fontana G. Hydrophilic and hydrophobic polymeric derivatives of anti-inflammatory agents such as aclofenac, ketoprofaen and ibuprofen. J. Biact. Comp. Polym. 6:1991;129-141.
51. Giammona G., Puglisi G., Cavallaro G., Spadaro A., Pitarresi G. Chemical stability and bioavailability of aciclovir coupled to α,β-poly(N-2-hydroxyethyl)-DL-aspartamide. J. Controlled Release. 33:1995;261-271.
52. Giammona G., Cavallaro G., Fontana G., Pitarresi G., Carlisi B. Coupling of the antiviral agent ribovuridine to polyaspartamide and in vitro drug release studies. J. Controlled Release. 54:1998;321-331.
53. 1H NMR spectroscopy and conformation of the conjugates. Bioconjug. Chem. 4:1993;554-559.
54. Zalipsky S., Menon-Rudolph S. Hydrazide derivatives of poly(ethylene glycol) and their conjugates. Harris J.M. Poly(ethylene glycol) Chemistry: Biotechnical and Biomedical Applications. second ed. 1998;319-341 Plenum, New York.
55. Giammona G., Carlisi B., Cavallaro G., Pitarresi G., Spampinato S. A new water-soluble synthetic polymer, α,β-polyasparthydrazide, as a potential plasma expander and drug carrier. J. Controlled Release. 29:1994;63-72.
56. Bonina F.P., Montenegro L., DeCaprariis P., Palagiano F., Trapani G., Liso G. In vitro and in vivo evaluation of polyoxyethylene indomethacin esters as dermal prodrugs. J. Controlled Release. 34:1995;223-232.
57. Needham D., McIntosh T.J., Lasic D.D. Repulsive interactions and mechanical stability of polymer-grafted lipid membranes. Biochim. Biophys. Acta. 1108:1992;40-48.
58. Torchilin V.P., Omelyanenko V.G., Papisov M.I., Bogdanov A.A. Jr., Trubetskoy V.S., Herron J.N., Gentry C.A. Poly(ethylene glycol) on the liposome surface: on the mechanism of polymer-coated liposome longevity. Biochim. Biophys. Acta. 1195:1994;11-20.
59. Blume G., Cevc G. Molecular mechanism of the lipid vesicle longevity in vivo. Biochim. Biophys. Acta. 1146:1993;157-168.
60. Maeda H., Matsumura T. Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carr. Syst. 6:1989;193-210.
61. Seymour L.W. Passive tumor targeting of soluble macromolecules and drug conjugates. Crit. Rev. Ther. Drug Syst. 9:1992;135-187.
62. Okamato C.T. Endocytosis and transcytosis. Adv. Drug Deliv. Rev. 29:1998;215-228.
63. Kee University, UK Patent No. 2270920, 1990.
64. A.J. Kirby, P.W. Lancaster, Structure and efficiency in intramolecular and enzymatic catalysis. Catalysis of amide and hydrolysis by the carboxy group of substituted maleamic acid, J. Chem. Soc., Perkin Trans. II (1972) 1204-1214.
65. F.M. Veronese, O. Schiavon, P. Caliceti, Protein delivery: PVP as a new polymer for protein conjugation, 24th Proc. Int. Symp. Controlled Release Bioact. Mater., 1997, pp. 507-508.
66. Veronese F.M., Visco C., Massarotto S., Benassi C.A., Ferruti P. New acrylic polymers for surface modification of enzymes of therapeutic interest and for enzyme immobilization. Ann. NY Acad. Sci. 501:1987;444-448.
67. Woodle M.C., Engbers C.M., Zalipsky S. New amphipatic polymer-lipid conjugates forming long-circulating reticuloendothelial system-evading liposomes. Bioconjug. Chem. 5:1994;493-496.
68. Kojima Y., Maeda H. Evaluation of poly(vinyl alcohol) for protein tailoring: improvements in pharmacokinetic properties of superoxide dismutase. J. Bioact. Comp. Polym. 8/2:1993;115-131.
69. Torchilin V.P., Voronkov J.I., Mazoev A.V. The use of immobilized streptokinase (Streptodekaza) for the therapy of thromboses. Ter. Ark. (Ther. Arch. Russ.). 54:1982;21-25.
70. E.I. Chazov, V.N. Smirnov, I.M. Torchilin, V.P. Moskivichev, G.M. Grimberg, A.Z. Skuja, G.I. Kleiner, Dextran derivatives of fibrinolysin, US Patent No. 4446316.
71. Tam S.C., Wong J.T.F. Modification of hemoglobin upon covalent coupling to dextran: enhanced stability against acid denaturation and reduced affinity for haptoglobin. Can. J. Biochem. 58:1980;732-736.
72. Larionova N.I., Kazanskaya N.R., Sacharov I.Yu., Mityushina G.V. Soluble high molecular weight derivatives of pancreatic trypsin inhibitor. Modification of pancreatic trypsin inhibitor by soluble polysaccharides activated by titanium tetrachloride. Biokhimiia. 45:1980;638-686.
73. Larionova N.I., Mityushina G.V., Kazanskaya N.F., Blidchenko Y.A., Berezin I.V. Carbohydrate-containing derivatives of the trypsin-kallikrein inhibitor aprotinin from bovine organs. I. Modification with lactose, characterization and behaviour of the preparation in vivo. Hoppe Sayler's Z. Physiol. Chem. 365:1984;791-797.
74. Larionova N.I., Mityushina G.V., Kazanskaya N.F., Blidchenko V.A., Berezin I.V. Carbohydrate-containing derivatives of the trypsin-kallikrein inhibitor aprotinin from bovine organs. II. Inhibitor coupled to the (carboxymethyl)dextran derivatives of D-galactose. Biol. Chem. Hoppe-Sayler's. 366:1985;743-748.
75. Abuchowsky A., Mc Coy J.R., Palczuck N.C., Van Es T., Davis F.F. Alteration of immulogical properties of bovine serum albumin by covalent attachment of poly(ethylene glycol). J. Biol. Chem. 252:1997;3578-3581.
76. Savoca K.V., Abuchowski A., Van. Es T., Davis F.F., Palczuk N.C. Preparation of a non-immunogenic arginase by the covalent attachment of poly(ethylene glycol). Biochim. Biophys. Acta. 578:1979;47-53.
77. Snider J., Neville C., Yuan L.C., Bullock J. Characterization of the heterogeneity of poly(ethylene glycol)-modified superoxide dismutase by chromatographic and electrophoretic techniques. J. Chromatagr. 599:1992;141-155.
78. F.M. Veronese, B. Saccà, O. Schiavon, P. Caliceti, L. Orsatti, P. Orsolini, PEG-peptide and protein delivery: a procedure to identify the PEGylation site, 26th Proc. Int. Symp. Controlled Release Bioact. Mater., Boston, MA, 1999.
79. O. Schiavon, F.M. Veronese, P. Caliceti, P. Orsolini, Method for identifying, or analyzing polymer linkage sites on macromolecules using aminoacid reporter binding, Eur. Patent Appl., 1998.
80. Sartore L., Caliceti P., Schiavon O., Monfardini C., Veronese F.M. Accurate evaluation method of the polymer content in monomethoxypoly(ethylene glycol)-modified proteins based on aminoacid analysis. Appl. Biochem. Biotechnol. 31:1991;213-221.
81. Snyder S.L., Sobocinsky P.Z. An improved 2,4,6-trinitrobenzenesulphonic acid method for the determination of amines. Anal. Biochem. 64:1975;284-288.
82. Habeeb A.F.S.A. Determination of free amino groups in proteins by trinitrobenzensulphonic acid. Anal. Biochem. 14:1966;328-336.
83. Uderfriend S., Stein S., Böhlen P., Dairman W., Leimgruber W., Weigele M. Fluorescamine: a reagent for assay of aminoacids, peptides, proteins and primary amines in the picomole range. Science. 78:1972;871-877.
84. Caliceti P., Schiavon O., Sartore L., Monfardini C., Veronese F.M. Active site protection of proteolytic enzymes by poly(ethylene glycol) surface modification. J. Bioact. Biocomp. Polym. 8:1993;41-50.
85. Monfardini C., Schiavon O., Caliceti P., Morpurgo M., Harris J.M., Veronese F.M. Branched monomethoxypoly(ethylene glycol) for protein modification. Bioconjug. Chem. 6:1995;62-69.
86. Veronese F.M., Caliceti P., Schiavon O. Branched and linear poly(ethylene glycol): Influence of the polymer structure on enzymological, pharmacokinetic, and immunological properties of protein conjugates. J. Bioact. Comp. Polym. 12:1997;196-207.
87. Ono K., Kai Y., Maeda H., Samizo T., Sakurai K., Nishimura H., Inada Y. Selective synthesis of 2,4-bis(O-methoxypoly(ethylene glycol))-6-chloro-s-triazine as a protein modifier. J. Biomat. Sci. Polym. Ed. 2:1991;61-65.
88. Pang S.N.J. Final report on the safety of poly(ethylene glycols) (PEGs) 6, 8, 32, 75, 150, 14M. J. Am. Coll. Toxicol. 12:1993;429-456.
89. G.M. Pawel, Poly(ethylene glycol), in: R.L. Davidson (Ed.), Handbook of Water Soluble Gums and Resins, McGraw-Hill, New York, 1980 (Chapter 8).
90. Bollinger M.E., Arredondo-Vega D.O.F., Santisteban I., Schwarz K., Hershfield M.S., Lederman H.M. Brief report: hepatic dysfunction as a complication of adenosine deaminase deficiency. New Engl. J. Med. 334:1996;1367-1371.
91. Weiss R.B. Hypersensitivity reactions. Semin. Oncol. 19:1992;458-477.
92. Peters B.G., Goeckner B.J., Ponzillo J.J., Velasquez W.S., Wilson A.L. Pegaspargase versus asparaginase in adult ALL: a pharmacoeconomic assessment. Hosp. Formul. 30:1995;388-393.
93. M.S. Hershfield, Biochemistry and immunology of poly(ethylene glycol) modified adenosine deaminase, in: J.M. Harris, S. Zalipsky (Eds.), Poly(ethylene glycol) Chemistry and Biological Applications, American Chemical Society, Washington, DC, 1998, p.145-154.
94. Hoogerbrugge P.M., VonBeusechem V.W., Kaptein L.C.M., Einerhand M.P.W., Valerio D. Gene therapy for adenosine deaminase deficiency. Br. Med. Bull. 51:1995;72-81.
95. Fairbanks L.D., Simmonds H.A., Hoogerbrugge P.M., Von Beusechem V.W., Valerio D., Moseley A., Levinsky R.J., Gaspar H.B., Morgan G. Biochemical and immunological status following gene therapy and PEG-ADA therapy for adenosine deaminase (ADA) deficiency. Adv. Exp. Med. Biol. 370:1994;391-394.
96. Veronese F.M., Monfardini C., Caliceti P., Schiavon O., Scrawen M.D., Beer D. Improvement of pharmacokinetic, immunological and stability properties of asparaginase by conjugation to linear and branched monomethoxy poly(ethylene glycol). J. Controlled Release. 40:1996;199-209.
97. Somack R., Saifer M.G.P., Williams L.D. Preparation of long-acting superoxide dismutase using high molecular weight poly(ethylene glycol) (41 000-72 000 Da). Free Rad. Res. Commun. 12-13:1991;553-562.
98. Boccu' E., Velo G.P., Veronese F.M. Pharmacokinetic properties of poly(ethylene glycol) derivatized superoxide dismutase. Pharmacol. Res. Commun. 14:1982;113-120.
99. Maksimenko A.V., Petrov A.D., Caliceti P., Konovalova G.G., Grigoryeva E.L., Schiavon O., Lankin V.Z., Veronese F.M. Biodistribution of a poly(ethylene glycol) modified superoxide dismutase in mice and its effect on myocardia ischemia treatments. Drug Deliv. 2:1995;39-43.
100. Saifer M.G., Somack R., Williams L.D. Plasma clearance and immunologic properties of long-acting superoxide dismutase prepared using 35 000-120 000 Da poly(ethylene glycol). Adv. Exp. Med. Biol. 366:1994;377-387.
101. Conover C.D., Linberg R., Gilbert C.W., Sham K.L., Shorr R.G.L. Effect of poly(ethylene glycol) conjugated bovine hemoglobin in both top-load and exchange transfusion rat models. Artif. Organs. 21:1997;1066-1075.
102. Song D., Olano M., Wilson D.F., Pastuszko A., Tammela O., Nhao K., Shorr R.G.L. Comparison of the efficacy of blood and poly(ethylene glycol)-hemoglobin in recovery of newborn piglets from hemorrhagic hypotension: effect on blood pressure, cortical oxygen, and extracellular dopamine in the brain. Transfusion. 35:1995;552-558.
103. Vangel P. Oxygenation of solid tumors. Techer B.A. Drug Resistance in Oncology. 1993;53-85 Marcel Dekker, New York.
104. Teicher B.A., Ara G., Herbst R., Takeuchi H., Keyes S., Northey D. PEG-hemoglobulin: effects on tumor oxynegation and responce to chemotherapy. In Vivo. 11:1997;301-312.
105. Teicher B.A., Ara G., Chen Y., Emi Y., Kakeji Y., Ikebe M., Maehara Y. PEG-hemoglobin: effects on tumor oxygenation and radiosensitization. Radiat. Oncol. Inv. 4:1996;200-210.
106. Breslow D.S., Edwards E.I., Newburg N.R. Divinyl ether-maleic anhydride (pyran) copolymer used to demonstrate the effect of molecular weight on biological activity. Nature. 246:1973;160-162.
107. Breslow D.S. Biologically active synthetic polymers. Pure Appl. Chem. 46:1976;103-113.
108. Hirano T., Todoroki T., Kato S., Yamamoto H., Caliceti P., Veronese F.M., Maeda H., Ohashi S. Synthesis of conjugate of superoxide dismutase with the copolymer of divinyl ether and maleic anhydride retaining enzymatic activity. J. Controlled Release. 28:1994;203-209.
109. Maeda H. Pharmacological uniqueness and clinical effects. Maeda H., Edo K., Ishida N. Neocarzinostation: The Past, Present and Future of Anticancer Drugs. 1997;Springer, Tokyo.
110. Zacks A., Klibanov A.M. Enzymatic catalysis in non-aqueous solvents. J. Biol. Chem. 263:1988;3194-3201.
111. Klibanov A.M. Why are enzymes less active in organic solvents? Tibtech. 15:1988;97-101.
112. Inada Y, Takahashi K., Yoshimoto T., Ajima A., Matsushima A., Saito Y. Application of poly(ethylene glycol)-modified enzymes in biotechnological processes: organic solvent soluble enzymes. Tibtech. 4:1986;190-194.
113. Inada Y., Yoshimoto T., Matsushima A., Saito Y. Engineering physicochemical and biological properties of proteins by chemical modification. Trends Biotech. 4:1984;68-73.
114. Takahashi K., Yoshimoto T., Ajima A., Inada Y. Poly(ethylene glycol)-modified catalase exhibits unexpectedly high activity in benzene. Biochem. Biophys. Res. Commun. 125:1984;761-766.
115. Bovara R., Ottolina G., Carrea G., Ferruti P., Veronese F.M. Modification of lipase from Pseudomonas sp., with poly(acryloyl morpholine) and study of its catalytic properties in organic solvents. Biotechnol. Lett. 16:1994;1069-1074.
116. Helene C. The anti-gene strategy: control of gene expression by triplex-forming-oligonucleotides. Anti-Cancer Drug Del. 6:1991;569-584.
117. De-Mesmaeker A., Haener R., Martin P., Moser H.E. Antisense nucleotides. Acc. Chem. Res. 28:1995;366-374.
118. Gold L. Oligonucleotides as research, diagnostic, and therapeutic agents. J. Biol. Chem. 270:1995;13581-13584.
119. Duguid J.G., Li C., Shi M., Logan M.J., Alila H., Rolland A., Tomlimson E., Sparrow J.T., Smith L.C. A physicochemical approach for predicting the effectiveness of peptide-based gene delivery systems for use in plasmid-based gene therapy. Biophys. J. 74:1998;2802-2814.
120. Manoharam M., Johnson L.K., Bennet C.F., Vickers T., Ecker D.J., Cowsert L.M:, Freier S.M., Cook P. Cholic acid oligonutide conjugates for antisens application. Bioorg. Med. Chem. Lett. 18:1994;3777-3781.
121. Shea R.G., Marsters J.C., Bishofberger N. Synthesis and hybridazation properties and antiviral activity of lipid-oligodesoxinucleotide conjugates. Nucleic Acids Res. 18:1990;3777-3779.
122. Boutorin A., Guskova L., Ivanova E., Kobetz N., Zarytova V., Ryte S., Yurchenko L., Vlassov V. Synthesis of alkylating oligonucleotides deriatives containing cholesterol or phenazinium residues at their 3′-terminus and their interaction with DNA within mammalian cells. FEBS Lett. 254:1989;129-131.
123. Bonora G.M., Ivanova E., Zarytova V., Burcovich B., Veronese F.M. Synthesis and characterization of high-molecular mass poly(ethylene glycol)-conjugated oligonucleotides. Bioconjug. Chem. 8:1997;793-797.
124. Jaschke A., Furste J.P., Nordhoff E., Hillekamp F., Cech D., Erdmann V.A. Synthesis and properties of oligodesoxyribonucleotide-poly(ethylene glycol) conjugates. Nucleic Acids Res. 22:1994;4810-4814.
125. Kawaguchi T., Asakana H., Tashiro Y., Juni K., Sueishi T. Stability, specific binding activity, and plasma concentration in mice of an oligodesoxynucleotide modified at 5′-terminal with poly(ethylene glycol). Biol. Pharm. Bull. 18:1995;474-478.
126. S.C. Gill, unpublished results.
127. Manoharam M., Tivel K.L., Andrade L.K., Mohan V., Condon T.P., Bennet F.C., Cook P.D. Oligonucleotides conjugates: alteration of the pharmacokinetic proerties of antisense agents. Nucleosides Nucleotides. 14:1995;969-973.
128. Bonora G.M., Tocco G., Zaramella S., Veronese F.M., Pliasunova P., Pokrovsky A., Ivanova E., Zaryota V. Antisense activity of an anti-HIV oligonucleotide conjugated to linear and branched high molecular weight poly(ethylene glycols). Farmaco. 53:1998;634-637.
129. G.T. Hermanson (Ed.), Bioconjugate Techniques, Academic Press, San Diego, 1996.
130. K. Mosbach (Ed.), Methods in Enzymology, vol. XLIV (Immobilized Enzymes), Academic Press, San Diego, 1976.
131. Zioudrou C., Wilchek M., Patchornick A. Conversion of the L-serine residue to an L-cysteine in peptides. Biochem. J. 4:1965;1811-1822.
132. Carlsson J., Drevin H., Axen R. Protein thiolation and reversible protein-protein conjugation N-succinimidyl 3-(2-pyridylthio)propionate, a new heterobifunctional reagent. Biochem. J. 173:1978;723-737.
133. Goodson R.J., Katre N. Site-directed pegylation of recombinant interleukin-2 at its glycosilation site. Biotechnology. 8:1990;343-346.
134. Hershfield M.S., Chaffee S., Koro-Johnson L., Mary A., Smith A.A., Short S.A. Use of site-directed mutagenesis to enhance the epitope-shielding effect of covalent modification of proteins with poly(ethylene glycol). Proc. Natl. Acad. Sci. USA. 88:1991;7185-7189.
135. Felix A.M., Lu Y., Campbell R.M. Pegylated peptides IV: enhanced biological activity of site directed pegylated GRF analogs. Int. J. Peptide Protein Res. 46:1995;253-264.
136. Efimov V.A., Pashkova I.N., Kalinkina A.L., Chakhmakhceva O.G. Synthesis of conjugates of oligonucleotides with poly(ethylene gycol). Bioorg. Khim. 19:1993;800-810.
137. Bonora G.M. Poly(ethylene glycol). A high efficiency liquid phase (HELP) for the large-scale synthesis of oligonucleotides. Appl. Biochem. Biophys. 54:1995;3-9.
138. Jaschke A., Bold R., Nordhoff E., Hillekamp F., Cech D., Erdmann V.A., Furste J.P. Synthesis and analytical characterization of RNA-poly(ethylene glycol) conjugates. Nucleosides Nucleotides. 15:1996;1519-1522.
139. Tarasow T.M., Timmermeir D., Zyrniewski C. Characterization of oligodesoxyribonulceotide-poly(ethylene glycol) conjugates by EMS. Bioconjug. Chem. 8:1997;89-92.
140. Burcovich B., Veronese F.M., Zarytova V., Bonora G.M. Branched poly(ethylene glycol) (bPEG) conjugated antisense oligonucleotides. Nucleosides Nucleotides. 17:1998;1567-1570.
141. Bonora G.M., Baldan A., Schiavon O., Ferruti P., Veronese F.M. Poly(N-acryloylmorpholine) as a new soluble support for the liquid-phase synthesis of oligonucleotides. Tetrahedron Lett. 37:1996;4761-4764.
142. Cuatrecases P., Anfinsen C.B. Affinity chromatography. Methods Enzymol. 22:1971;345-378.
143. Herman S., Hooftman G., Schacht E. Poly(ethylene glycol) with reactive endgroups: I. modification of proteins. J. Bioact. Comp. Polym. 10:1995;145-187.
144. Morpurgo M., Bayer E.A., Wilchek M. N-hydroxysuccinimide carbonates and carbamates are useful reactive reagents for coupling ligands to lysines on proteins. J. Biochem. Biophys. Methods. 38:1999;17-28.
145. Morpurgo M., Veronese F.M., Kachensky D., Harris J.M. Preparation and characterization of poly(ethylene glycol) vinyl sulfone. Bioconjug. Chem. 7:1996;363-368.
146. PEG-Intron could move Enzon into profit, SCRIP (1999) No. 2424, 9.
147. Eur. Patent No. 0,340,741 from Sumitomo, Japan.
148. Newkome G.R., Yao Z., Baker G.R., Gupta V.K., Russo P.S., Saunders M.J. Cascade molecules: synthesis and characterization of a benzene[9]-arboral. J. Am. Chem. Soc. 108:1986;849-850.
149. F.M. Veronese, C. Mammucari, S. Lora, P. Caliceti, O. Schiavon, Influence of PEGylation on the release of low and high molecular weight compounds from PVA matrices, J. Bioact. Comp. Polym. (1999) in press.